*   **Intention-to-treat:** Yes
*   **Follow-up period:** 52 week
*   **Loss to follow-up:** 39%
*   **ITT anlaysis**

| | Tiotropium+placebo | Tiotropium+Salmeterol | Tiotropium+Fluticasone-Salmeterol |
| :---------------- | :------------------- | :-------------------- | :---------------------------------- |
| Number | 156 | 148 | 145 |
| Age | 68,1±8,9 | 67,6±8,2 | 67,5±8,9 |
| Sex (M) | 53,8% | 57,4% | 57,9% |
| Ethnicity (White) | 97,4% | 98,0% | 99,3% |

**Inclusion**
- At least 1 exacerbation of COPD that required treatment with systemic steroids or antibiotics within the 1 year before randomization
- Age older than 35 years
- A smoking history of ≥10 pack yrs
- FEV₁≤65% pred, in post-bronchodilator FEV₁ and a FEV₁/FVC ratio ≤70%

**Exclusion**
- A history of physician-diagnosed asthma before 40 years of age
- Those with a history of physician-diagnosed chronic congestive heart failure with known persistent severe left ventricular dysfunction
- Use of systemic corticosteroids
- Known hypersensitivity or intolerance to tiotropium, salmeterol or fluticasone-salmeterol
- A history of severe glaucoma or severe urinary tract obstruction
- A history of previous lung transplantation or lung volume reduction surgery
- A history of diffuse bilateral bronchiectasis
- Women who were pregnant or lactating

**Results**

| | Tiotropium+placebo | Tiotropium+Fluticasone-Salmeterol |
| :-------------------------------- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| | tiotropium, 18 μg once daily, plus placebo inhaler, 2 puffs twice daily | tiotropium, 18 μg once daily, plus fluticasone-salmeterol (Advair [GlaxoSmithKline]), 250/25 μg/puff, 2 puffs twice daily. |
| Number | 156 | 145 |
| Adjusted change FEV₁* | 0,027 L | 0,086 L |
| Health status (SGRQ-C) Total score | -4,5 | -8,6 |
| Exacerbations All exacerbations | 98 (62,8%) | 87 (60,0%) |
| Hospitalizations for acute exacerbations | 49 | 26 |
| | | 0,53 (0,33 to 0,86) |

### 근거표 8-3: LABA + LAMA vs LAMA

| 연구수 | 연구설계 | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 2 | 무작위대조군 | 없음 | 없음 | 있음 | 없음 | 없음 | 중등도 |

*   **Author, year publication:** Donald A Mahler et al., 2012
*   **Title:** Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
*   **Country:** Study 1: 186 centers in 14 countries
*   **Setting/Design:** Double-blind tiotropium 18 μg+Indacaterol 150 μg once daily vs. tiotropium 18 μg+placebo
*   **Time frame:** 12-week study
*   **Randomization method:** An automated interactive voice response system and was stratified by COPD severity
*   **Allocation concealment:** Yes (An automated interactive voice response system)
*   **Blinding:**
    *   - Participants: Yes
    *   - The blinding of indacaterol and placebo continued until the study

<PAGE>121